Hepatoma and Peliosis Hepatis Developing in a Patient with Fanconi's Anemia

After assessment of tumor histology, the next important factor to consider in the selection of a chemotherapy regime is organ function. Patients who are to receive chemotherapy require careful assessment of liver function prior to treatment to determine which drugs may not be appropriate, and which drug doses should be modified. Following therapy abnormalities of liver function tests may be due to the therapy rather than to progressive disease, and this distinction is of critical importance. Furthermore, not all abnormalities in liver function are due to the tumor or its treatment, and other processes, such as hepatitis, must be kept in mind. This article reviews the hepatic toxicity of chemotherapeutic agents, and suggests dose modifications based upon liver function abnormalities. Emphasis is placed on agents known to be hepatotoxic, and those agents with hepatic metabolism.

show abstract

“…The chronic use of any 17-alkyl androgen has the potential for the development of hepatic adenocarcinomas [131,132].…”

Section: Hormonesmentioning

confidence: 99%

Hepatotoxicity of Chemotherapy

2001

View full text Add to dashboard Cite

show abstract

“…Peliosis hepatis has also been reported with the use of AAS (108 -111). Lastly, there have also been isolated reports of AAS use resulting in carcinomas of the liver (112)(113)(114)(115)). An exhaustive review of the literature by the authors failed to show any clear increase in the incidence of liver cancer associated with AAS use, and virtually all clinical studies of AAS-associated hepatoma have been isolated case reports.…”

Section: Muscular-skeletal Injurymentioning

confidence: 99%

Anabolic-Androgenic Steroid Therapy in the Treatment of Chronic Diseases

Basaria

Wahlstrom

Dobs

2001

The Journal of Clinical Endocrinology &Amp; Metabolism

218

170

View full text Add to dashboard Cite

The purpose of this study was to review the preclinical and clinical literature relevant to the efficacy and safety of anabolic androgen steroid therapy for palliative treatment of severe weight loss associated with chronic diseases. Data sources were published literature identified from the Medline database from January 1966 to December 2000, bibliographic references, and textbooks. Reports from preclinical and clinical trials were selected. Study designs and results were extracted from trial reports. Statistical evaluation or meta-analysis of combined results was not attempted.Androgenic anabolic steroids (AAS) are widely prescribed for the treatment of male hypogonadism; however, they may play a significant role in the treatment of other conditions as well, such as cachexia associated with human immunodeficiency virus, cancer, burns, renal and hepatic failure, and anemia associated with leukemia or kidney failure. A review of the anabolic effects of androgens and their efficacy in the treatment of these conditions is provided. In addition, the numerous and sometimes serious side effects that have been known to occur with androgen use are reviewed.Although the threat of various side effects is present, AAS therapy appears to have a favorable anabolic effect on patients with chronic diseases and muscle catabolism. We recommend that AAS can be used for the treatment of patients with acquired immunodeficiency syndrome wasting and in severely catabolic patients with severe burns. Preliminary data in renal failure-associated wasting are also positive. Advantages and disadvantages should be weighed carefully when comparing AAS therapy to other weight-gaining measures. Although a conservative approach to the use of AAS in patients with chronic diseases is still recommended, the utility of AAS therapy in the attenuation of severe weight loss associated with disease states such as cancer, postoperative recovery, and wasting due to pulmonary and hepatic disease should be more thoroughly investigated. (J Clin Endocrinol Metab 86: 5108 -5117, 2001)

show abstract

“…As for the type of androgen responsible for the HCC, the accumulated data show that nonalkylated androgens are not associated with HCC incidence, while the associ ation of CI7-alkylated androgens and HCC is well docu mented [1][2][3][4][5][6][7][8][9][10][11],…”

Section: Discussionmentioning

confidence: 99%

“…Since 1971, when Bernstein et al [1] described a case of hepatocellular carcinoma (HCC) in a patient with Fanconi's anemia treated with oxymetholone, 20 more patients were reported to have developed HCC following adminis tration of 17-alkylated anabolic steroids, e.g. oxymetho lone or methyltestosterone [2][3][4][5][6][7][8][9][10][11],…”

mentioning

confidence: 99%

Androgen-Associated Hepatoma in a Hemodialysis Patient

Zevin¹,

Turani²,

Cohen³

et al. 1981

Nephron

View full text Add to dashboard Cite

A patient on hemodialysis treatment developed hepatocellular carcinoma (HCC) after long-term therapy with androgenic anabolic steroids. The tumor progressed very rapidly, and there was no evidence of regression despite discontinuation of the drug. In view of the evidence of an increased incidence of malignancy in patients with chronic uremia and hemodialysis, and of the higher frequency of HCC correlated to treatment with C17-alkylated anabolic steroids, it is necessary to further evaluate the efficiency of this treatment in the aforementioned group of patients.

show abstract

Hepatoma and Peliosis Hepatis Developing in a Patient with Fanconi's Anemia

Cited by 150 publications

References 10 publications

Hepatotoxicity of Chemotherapy

Hepatotoxicity of Chemotherapy

Anabolic-Androgenic Steroid Therapy in the Treatment of Chronic Diseases

Androgen-Associated Hepatoma in a Hemodialysis Patient

Contact Info

Product

Resources

About